Latest Pricing NewsRSS

23:51 EDT 21st August 2017 | BioPortfolio

Tom Price: China an ‘incredible partner’ in controlling synthetic opioid production

During a visit to China, HHS head Tom Price said the country was doing a good job stemming the production of synthetic opioids like fentanyl.

Zeel Brings On-Demand Massages To Wilmington

NEW YORK, Aug. 21, 2017 /PRNewswire/ -- Zeel, the ultimate source for the best in-home massages, and 2017 Inc. 500 recipient, launches today in Wilmington, North Carolina. Carolinian residents and vacationers in this beachside resort city can now order a same-day spa-quality massage to homes, hotels, workplaces, events, or the beach, just in time for Labor Day Weekend. The launch furthers Zee...

Compare your own practice patterns to the national average. Here’s how.

In an era of increasing transparency in medicine, the Centers for Medicare & Medicaid Services (CMS) has been publishing data annually on payments to individual physicians since 2014. The database, officially called the Medicare Provider Utilization and Payment Data: Physician and Other Supplier Public Use File, has been a window (albeit a cracked and opaque […]

Understanding Future Market Trends and Reimbursement Scenario Are Crucial for Identifying Opportunities in the Leadless Pacemakers Market, Says Infiniti Research

Infiniti Research recently assessed the growth prospects of the leadless pacemaker devices market in Europe for a leading manufacturer of medical devices. The aim of this market assessment study was to understand the market landscape for leadless pacemakers across the target regions (the UK, France, Italy, Germany, Spain, Netherlands, and Switzerlan...

Insider Selling: Moleculin Biotech, Inc. (MBRX) Major Shareholder Sells $170,000.00 in Stock

Moleculin Biotech, Inc. major shareholder Waldemar Priebe sold 100,000 shares of the business's stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $1.70, for a total transaction of $170,000.00.

STAT Plus: Pharmalittle: Hikma makes big price hikes; controversy over Glaxo hepatitis B vaccine supplies

West Ward Pharmaceuticals, the U.S. division of Hikma, raised the price of six drugs by 75 percent to 430 percent, and the mean increase was 237 percent.

Regeneron Pharmaceuticals, Inc. (REGN) Chairman Sells $5,165,287.62 in Stock

Regeneron Pharmaceuticals, Inc. Chairman P Roy Vagelos sold 10,986 shares of the company's stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $470.17, for a total value of $5,165,287.62.

The University of Virginia Health System and Premier Inc. Create Strategic Partnership

Academic health system engages Premier to drive enterprise-wide improvements in quality and costs The University of Virginia Health System (UVA), a 600-bed academic medical center serving the Commonwealth, Mid-Atlantic and beyond, has signed a multi-year agreement with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to access tot...

Herbalife Announces Self-Tender Offer Seeking to Purchase up to $600 Million of Its Outstanding Common Shares

Herbalife Ltd. (NYSE: HLF) (“Herbalife” or “the Company”) announced today it has commenced a “modified Dutch auction” self-tender offer to purchase for cash up to an aggregate of $600 million of shares of its common stock at a per share price not less than $60.00 nor greater than $68.00. For each share tendered, shareholders will also receive a ...

Ned Carlson Appointed CEO of Trumpet Behavioral Health

Trumpet Behavioral Health, LLC announced today that it has appointed Ned Carlson as Chief Executive Officer. Trumpet is a leading provider of behavioral health services, specializing in the treatment of children, adolescents, and adults with Autism Spectrum Disorder (“ASD”) and developmental disabilities, using the principles of Applied Behavior Analys...

Quadax Inc. Appoints Walt Williams as Director of Revenue Cycle Optimization & Strategy

CLEVELAND, Aug. 21, 2017 /PRNewswire/ -- Quadax Inc., a healthcare information technology leader in providing revenue cycle optimization software and services, is pleased to announce the recent appointment of Walt Williams as Quadax's Director, Revenue Cycle Optimization & Strategy. Williams, an innovator in laboratory revenue cycle management and payer strategy, will be responsible for e...

Pharma industry ‘getting away with murder’ abroad thanks to Trump’s policies

President Trump angrily accused the pharmaceutical industry of "getting away with murder" on drug pricing. Yet his policies are helping them do that abroad.

Merck KGaA (MRK) Given a 105.00 Price Target by Goldman Sachs Group, Inc. (The) Analysts

The brokerage currently has a neutral rating on the healthcare company's stock. MRK has been the subject of a number of other reports.

Public Service Credit Union Kicks Off Fundraiser for Children’s Hospital Colorado

PSCU’s Kickoff for Kids to give away FREE Denver Broncos tickets* in support of Children’s Miracle Network Lone Tree, CO (PRWEB) August 21, 2017 Public Service Credit Union (PSCU) Kickoff for Kids Fundraiser is helping to make miracles happen at Children’s Hospital Colorado, one dollar at a time. August 18 through September 16, 2017, all 28 PSCU locations along the Front Range will be rais...

Biogen Inc.

The brokerage presently has a $338.00 price target on the biotechnology company's stock. Goldman Sachs Group, Inc. 's price objective points to a potential upside of 19.96% from the company's previous close.

LifeCare Holdings, Inc. Announces Second Quarter Results

PLANO, Texas, Aug. 14, 2012 /PRNewswire/ -- LifeCare Holdings, Inc. (the "Company") today announced its operating results for the second quarter ended June 30, 2012.  Three Months Ended June 30, 2012 Net Revenues Our net patient service revenue of $121.0 million for the three months ended June 30, 2012, increased by $25.0 million, or 26.0%, from the comparable period in 2011. Pa...

Hikma Jacks Up Price of U.S. Drugs by 430%

  Life Sciences Jobs   ...

3 Hot Biotech Stocks That Cost Less than a Cup of Coffee

August 21, 2017Whats the cost of a cup of coffee, these days? Probably varies depending on where you go, but there are some promising biotech stocks that are selling for...

US Congress to investigate Copaxone price hikes

Teva has raised the price of Copaxone 10-fold since 1996, two US Congressmen claim.

McKesson Corporation (MCK) Downgraded to Strong Sell at BidaskClub

Several other analysts also recently commented on MCK. Jefferies Group LLC raised shares of McKesson Corporation from a hold rating to a buy rating and set a $153.00 price objective on the stock in a research report on Thursday, July 27th.

Mylan N.V. (MYL) Upgraded at Citigroup Inc.

They currently have $42.00 price objective on the stock, up from their previous price objective of $36.00. A number of other equities research analysts also recently weighed in on the company.

Citigroup Inc. Lowers Teva Pharmaceutical Industries Limited (TEVA) to Neutral

The brokerage currently has $19.00 price objective on the stock, down from their prior price objective of $32.00. TEVA has been the subject of several other reports.

Pfizer, Inc. (PFE) Stock Rating Reaffirmed by Jefferies Group LLC

's stock had its "hold" rating reissued by equities researchers at Jefferies Group LLC in a report issued on Friday. They currently have a $35.00 price objective on the biopharmaceutical company's stock.

ASIAPACIFIC DENTAL CONSUMABLES MARKET FORECAST 20172025 [Report Updated: 16082017] Prices from USD $1250

KEY FINDINGSThe AsiaPacific dental consumables market is expected to show the fastest growth between 20172025 and is predicted to rise with an anticipated CAGR of 6.97%, generating $9533 million over this forecast period. MARKET INSIGHTSThe continuous rise in the disposable income of the evergrowing aging population and a rise in the general awareness regarding dental hygiene are the major drivers...

Biopharmx Corp (BPMX) versus Arrowhead Pharmaceuticals (ARWR) Critical Survey

Biopharmx Corp and Arrowhead Pharmaceuticals are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. This is a breakdown of recent recommendations and price targets for Biopharmx Corp and Arrowhead Pharmaceutica...

Quick Search

review and buy Pricing market research data and corporate reports here